Short answer
Journey Medical Corp (DERM) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 11.2% year over year) with net income of −$1M.
Q3 2026 key financials · XBRL
- Revenue
- $19M
- +11.2% YoY · +6.1% QoQ
- Net income
- −$1M
- +43.2% YoY · −321.5% QoQ
- Operating margin
- -2.8%
- EPS (diluted)
- −$0.05
- +44.4% YoY · −400.0% QoQ
Source: XBRL data from the Journey Medical Corp (DERM) Q3 2026 10-Q on SEC EDGAR. USD.
Journey Medical Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $19.0M, up $1.3M YoY, driven by Emrosi sales
- Operating loss $0.5M vs $1.5M YoY, operating margin -2.8% vs -8.7%
- Best performer Emrosi: $9.0M, up $4.1M; worst Qbrexza: $5.6M, down $1.8M
- Cash $22.3M vs $24.1M at December 31, 2025; nine-month operating cash use $2.3M
- Going-concern uncertainty, potential debt or equity financing needs, generic competition and Qbrexza coverage headwinds
Risk Factors
- No material changes to risk factors disclosed since the 2025 Form 10-K
- Carried-forward business risk: unidentified risks may materially adversely affect operations
- Carried-forward financial risk: risks may materially affect financial condition
- Carried-forward performance risk: risks may materially affect results of operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Journey Medical Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.